Shannon Matheny

2.4k total citations · 1 hit paper
36 papers, 1.0k citations indexed

About

Shannon Matheny is a scholar working on Oncology, Radiology, Nuclear Medicine and Imaging and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Shannon Matheny has authored 36 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Oncology, 19 papers in Radiology, Nuclear Medicine and Imaging and 17 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Shannon Matheny's work include Monoclonal and Polyclonal Antibodies Research (12 papers), Radiopharmaceutical Chemistry and Applications (10 papers) and HER2/EGFR in Cancer Research (8 papers). Shannon Matheny is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (12 papers), Radiopharmaceutical Chemistry and Applications (10 papers) and HER2/EGFR in Cancer Research (8 papers). Shannon Matheny collaborates with scholars based in United States, France and United Kingdom. Shannon Matheny's co-authors include Erwin G. Van Meir, Fatima W. Khwaja, Eric A. Severson, Daniel J. Brat, Balveen Kaur, Unnur P. Thorgeirsson, Takemi Akahane, Arturo Molina, Glenn Merlino and Valentina M. Factor and has published in prestigious journals such as Journal of Clinical Investigation, Journal of Clinical Oncology and Blood.

In The Last Decade

Shannon Matheny

35 papers receiving 986 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Hypoxia and the hypoxia-inducible-factor pathway in glioma growth andangiogenesis

2005 540 citations Balveen Kaur, Fatima W. Khwaja et al. Neuro-Oncology profile →

Peers

Countries citing papers authored by Shannon Matheny

Since Specialization

Citations

This map shows the geographic impact of Shannon Matheny's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shannon Matheny with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shannon Matheny more than expected).

Fields of papers citing papers by Shannon Matheny

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shannon Matheny. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shannon Matheny. The network helps show where Shannon Matheny may publish in the future.

Co-authorship network of co-authors of Shannon Matheny

This figure shows the co-authorship network connecting the top 25 collaborators of Shannon Matheny. A scholar is included among the top collaborators of Shannon Matheny based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shannon Matheny. Shannon Matheny is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Targeting CD74 in B-cell non-Hodgkin lymphoma with the antibody-drug conjugate STRO-001 2023 ·Oncotarget ·Xiaofan Li, Cristina L. Abrahams, Abigail Yu, Millicent Embry, Robert Henningsen, Venita DeAlmeida, Shannon Matheny, Toni Kline, Alice Yam, Ryan Stafford, Trevor J. Hallam, Mark Lupher, Arturo Molina	5
2	Abstract CT125: STRO-002-GM1, a first in human, phase 1 study of STRO-002, an anti-folate receptor alpha (FRα) antibody drug conjugate (ADC), in patients with advanced platinum-resistant/refractory epithelial ovarian cancer (OC), including fallopian tube or primary peritoneal cancers 2020 ·Cancer Research ·R. Wendel Naumann, Denise Uyar, John W. Moroney, Fadi S. Braiteh, Russell J. Schilder, John P. Diaz, Erika Hamilton, Sami Diab, Lainie P. Martin, David M. O’Malley, Richard T. Penson, Clifford DiLea, (unknown), Venita DeAlmeida, Shannon Matheny, Arturo Molina	2
3	138 Phase 1 dose-escalation study of STRO-002, an anti-folate receptor alpha (FRα) antibody drug conjugate (ADC), in patients with advanced platinum-resistant/refractory epithelial ovarian cancer (OC) 2020 ·R. Wendel Naumann, Fadi Braiteh, John P. Diaz, Erika Hamilton, Sami Diab, Russell J. Schilder, John W. Moroney, Lainie P. Martin, Denise Uyar, David M. O’Malley, Richard T. Penson, Clifford DiLea, (unknown), Venita DeAlmeida, (unknown), Shannon Matheny, A. Molina	2
4	Preliminary Results of an Ongoing Phase 1 Dose Escalation Study of the Novel Anti-CD74 Antibody Drug Conjugate (ADC), STRO-001, in Patients with B-Cell Non-Hodgkin Lymphoma 2020 ·Blood ·Nirav N. Shah, (unknown), Leslie Popplewell, Charalambos Andreadis, Jason M. Melear, Alexander I. Spira, (unknown), Sudhir Manda, John M. Burke, Saurabh Chhabra, Jeff P. Sharman, Amrita Krishnan, Nina Shah, Clifford DiLea, (unknown), (unknown), Shannon Matheny, John P. Leonard, Arturo Molina	8
5	Preliminary Results of a Phase 1 Dose Escalation Study of the First-in-Class Anti-CD74 Antibody Drug Conjugate (ADC), STRO-001, in Patients with Advanced B-Cell Malignancies 2019 ·Blood ·Nirav N. Shah, Amrita Krishnan, Nina Shah, John M. Burke, Jason M. Melear, Alexander I. Spira, Leslie Popplewell, Charalambos Andreadis, Saurabh Chhabra, Jeff P. Sharman, Jonathan L. Kaufman, Jonathon B. Cohen, Rubén Niesvizky, Thomas G. Martin, Clifford DiLea, (unknown), Shannon Matheny, John P. Leonard, Arturo Molina	16
6	Abstract CT104: A Phase I open-label, safety, pharmacokinetic, and preliminary efficacy study of STRO-001, an anti-CD74 antibody drug conjugate, in patients with advanced B-cell malignancies 2019 ·Cancer Research ·Nirav N. Shah, Amrita Krishnan, Nina Shah, John M. Burke, Jason M. Melear, Alexander I. Spira, Jonathan L. Kaufman, Jonathon B. Cohen, Rubén Niesvizky, Leslie Popplewell, Saurabh Chhabra, Jeff P. Sharman, Thomas Martin, Shannon Matheny, John P. Leonard, Arturo Molina	1
7	Abstract C095: Antitumor activity of STRO-002, a novel anti-folate receptor-α (FRα) antibody drug conjugate (ADC), in patient-derived xenograft (PDX) models and preliminary phase I dose escalation safety outcomes in patients with ovarian carcinoma (OC) 2019 ·Molecular Cancer Therapeutics ·Denise Uyar, Russell J. Schilder, R. Wendel Naumann, Fadi S. Braiteh, Erika Hamilton, Sami Diab, John W. Moroney, Richard T. Penson, Jennifer Smith, Cristina L. Abrahams, (unknown), Venita DeAlmeida, Shannon Matheny, Arturo Molina	3
8	Ankle Strength Deficits in a Cohort of College Athletes With Chronic Ankle Instability 2018 ·Journal of Sport Rehabilitation ·(unknown), Shannon Matheny, (unknown), (unknown), Joseph J. Glutting, C. Buz Swanik, Thomas W. Kaminski	16
9	Targeting CD74 in multiple myeloma with the novel, site-specific antibody-drug conjugate STRO-001 2018 ·Oncotarget ·Cristina L. Abrahams, Xiaofan Li, Millicent Embry, Abigail Yu, Stellanie Krimm, S.A. Krueger, Nancy Greenland, Kwun Wah Wen, Chris Jones, Venita DeAlmeida, Willy A. Solis, Shannon Matheny, Toni Kline, Alice Yam, Ryan Stafford, Arun P. Wiita, Trevor J. Hallam, Mark Lupher, Arturo Molina	45
10	High Frequency of CD74 Expression in B-Cell Non-Hodgkin's Lymphoma (NHL) and Targeting with SΤRO-001, a Novel Anti-CD74 Antibody Drug Conjugate (ADC) with Potent I n Vitro Cytotoxicty and In Vivo Anti-Tumor Activity 2017 ·Blood ·Abigail Yu, Cristina L. Abrahams, Millicent Embry, Xiaofan Li, Shuchun Zhao, Robert Henningsen, Venita DeAlmeida, Shannon Matheny, Toni Kline, Alice Yam, Ryan Stafford, Yasodha Natkunam, Trevor J. Hallam, Mark Lupher, Arturo Molina	1
11	CD74 Is Expressed in Relapsed and Refractory Multiple Myeloma and Can be Targeted with a Novel Anti-CD74 Antibody Drug Conjugate, SΤRO-001 2017 ·Blood ·Millicent Embry, Xiaofan Li, Abigail Yu, Cristina L. Abrahams, Nancy Greenland, Kwun Wah Wen, Chris Jones, Venita DeAlmeida, Stellanie Krimm, S.A. Krueger, Shannon Matheny, Toni Kline, Alice Yam, Ryan Stafford, Arun P. Wiita, Trevor J. Hallam, Mark Lupher, Arturo Molina	1
12	3009 Activity of rociletinib in EGFR mutant NSCLC patients with a history of CNS involvement 2015 ·European Journal of Cancer ·Andréa Varga, D. Ross Camidge, Lecia V. Sequist, Heather A. Wakelee, S.‐H.I. Ou, (unknown), V. Papadimitrakopoulou, S. Gadgeel, Tarek Mekhail, Geoffrey R. Oxnard, Mark A. Socinski, Benjamin Solomon, Heping Yu, Shannon Matheny, Darrin Despain, Jean‐Charles Soria	11
13	10LBA Interim phase 2 results of study CO-1686-008: A phase 1/2 study of the irreversible, mutant selective, EGFR inhibitor rociletinib (CO-1686) in patients with advanced non small cell lung cancer 2014 ·European Journal of Cancer ·J.C. Soria, Lecia V. Sequist, (unknown), Heather A. Wakelee, S. Gadgeel, Andreea Varga, Huiqing Yu, Benjamin Solomon, S.-H.I. Ou, V. Papadimitrakopoulou, Geoffrey R. Oxnard, (unknown), Rafał Dziadziuszko, Bo H. Chao, Alexander I. Spira, (unknown), Tarek Mekhail, Shannon Matheny, Jason B. Litten, (unknown)	4
14	Response to androgen signaling (AS)-directed therapy after treatment with abiraterone acetate (AA) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Post hoc analysis of study COU-AA-302. 2014 ·Journal of Clinical Oncology ·Matthew R. Smith, Shannon Matheny, Fred Saad, Dana E. Rathkopf, Peter F.A. Mulders, Johann S. de Bono, Eric J. Small, Neal D. Shore, Karim Fizazi, Thian Kheoh, Jinhui Li, Mary B. Todd, Thomas W. Griffin, Margaret K. Yu, Charles J. Ryan	2
15	Relationship of baseline PSA and degree of PSA decline to radiographic progression-free survival (rPFS) in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC): Results from COU-AA-302. 2013 ·Journal of Clinical Oncology ·Charles J. Ryan, Anil Londhe, Arturo Molina, Matthew R. Smith, Johann S. de Bono, Peter Mulders, Dana E. Rathkopf, Fred Saad, Christopher J. Logothetis, Karim Fizazi, Howard I. Scher, Eric J. Small, Shannon Matheny, Thian Kheoh, Thomas W. Griffin	8
16	Randomized double-blind, comparative study of abiraterone acetate (AA) plus low-dose prednisone (P) plus androgen deprivation therapy (ADT) versus ADT alone in newly diagnosed, high-risk, metastatic hormone-naive prostate cancer (mHNPC). 2013 ·Journal of Clinical Oncology ·Karim Fizazi, Julie S. Larsen, Shannon Matheny, Arturo Molina, Jinhui Li, Mary B. Todd, Margaret K. Yu, Thian Kheoh, NamPhuong Tran	5
17	Vascular endothelial growth factor‐D is a survival factor for human breast carcinoma cells 2005 ·International Journal of Cancer ·Manabu Akahane, Takemi Akahane, Shannon Matheny, (unknown), Eijiro Okajima, Unnur P. Thorgeirsson	20
18	VEGF contributes to mammary tumor growth in transgenic mice through paracrine and autocrine mechanisms 2005 ·Laboratory Investigation ·(unknown), Shannon Matheny, Takemi Akahane, Valentina M. Factor, (unknown), Glenn Merlino, Unnur P. Thorgeirsson	71
19	Hypoxia and the hypoxia-inducible-factor pathway in glioma growth andangiogenesis breakdown → 2005 ·Neuro-Oncology ·Balveen Kaur, Fatima W. Khwaja, Eric A. Severson, Shannon Matheny, Daniel J. Brat, Erwin G. Van Meir	540
20	A Rapid Method for Screening Antibodies to Plasmodium yoelii Liver Stages by Immunofluorescence 1987 ·Journal of Parasitology ·Martha Sedegah, M F Leef, Shannon Matheny, Richard L. Beaudoin	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact